Journal: Biology of Reproduction

Article Title: Anti-Müllerian hormone is a survival factor and promotes the growth of rhesus macaque preantral follicles during matrix-free culture †

doi: 10.1093/biolre/iox181

Figure Lengend Snippet: The effects of anti-Müllerian hormone on the macaque secondary follicle growth (follicle diameter) at culture week 2 (A; n = 10–19 follicles), the production (media concentration) of estradiol (B; n = 10 follicles) and vascular endothelial growth factor (VEGF; C; n = 10 follicles) by in vitro-developed macaque small antral follicles at culture week 3, and oocyte maturation in in vitro-developed macaque small antral follicles following recombinant hCG treatment at culture week 5 as represented by an metaphase II oocyte (D) which developed to the morula stage (E) when fertilized via in vitro fertilization. Data in panels A, B, and C are presented as the mean ± SEM. CTRL, control; AMH, recombinant human anti-Müllerian hormone addition during culture weeks 0–2; *, significant difference with P < 0.05; scale bar = 25 μm.

Article Snippet: Isolated secondary follicles (diameter = 140–225 μm) from each of the three animals were randomly assigned to five groups (15 follicles/monkey/group) for 5 weeks of matrix-free culture as described above: (a) control media-only, (b) 9.6 × 10 5 pfu/ml NTC shRNA-vector incubation for 24 h, (c) 9.6 × 10 5 pfu/ml AMH shRNA-vector incubation for 24 h, (d) 9.6 × 10 5 pfu/ml AMH shRNA-vector incubation for 24 h +100 ng/ml recombinant human AMH (rhAMH; 1737-MS; disulfide-linked C-terminal homodimer; R&D Systems, Inc.; based on a preliminary dose-response study using 50 and 100 ng/ml rhAMH) during culture weeks 0–2 (exogenous AMH replacement before antrum formation following endogenous AMH depletion) [ 4 ], and (e) 100 ng/ml rhAMH during culture weeks 0–2.

Techniques: Concentration Assay, In Vitro, Recombinant, Control

Journal: Cell Reports Medicine

Article Title: Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia

doi: 10.1016/j.xcrm.2020.100059

Figure Lengend Snippet: Evaluation of Antiviral Activity of Remdesivir-Diltiazem in Vero E6 Cells and in HAE (A and B) Dose-response curves of remdesivir and remdesivir-diltiazem combination (11.5 μM fixed diltiazem concentration) at 48 hpi (A) and 72 hpi (B) in Vero E6 cells. # Estimated IC 50 and SI values. (C) Effect of antiviral treatment on virally induced cytopathic effects in Vero E6 cells (scale bar, 150 μM). (D and E) Relative intracellular viral genome quantification and trans-epithelial resistance (TEER in Ω/cm 2 ) between the apical and basal poles in nasal and bronchial HAE at (D) 48 and (E) 72 hpi. Results are expressed in relative viral production compared to the infected untreated control and relative TEER compared to t = 0 (before infection). Data (means ± SDs) from 3 independent experiments are shown. Statistical significance was calculated by 1-way ANOVA; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗∗p < 0.0001 versus untreated group. See also Figure S2 .

Article Snippet: Nonetheless, the addition of 11.5 μM diltiazem significantly potentiated the antiviral effect of remdesivir, as evidenced by the shift on dose-response curves toward IC 50 values at least 3- and 2-fold lower than those observed for remdesivir monotherapy at 48 and 72 hpi, respectively ( A–4C).

Techniques: Activity Assay, Concentration Assay, Infection

Journal: Cell Reports Medicine

Article Title: Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia

doi: 10.1016/j.xcrm.2020.100059

Figure Lengend Snippet:

Article Snippet: Nonetheless, the addition of 11.5 μM diltiazem significantly potentiated the antiviral effect of remdesivir, as evidenced by the shift on dose-response curves toward IC 50 values at least 3- and 2-fold lower than those observed for remdesivir monotherapy at 48 and 72 hpi, respectively ( A–4C).

Techniques: Recombinant, Expressing, Proliferation Assay, Software